250 related articles for article (PubMed ID: 20064265)
1. Chemosensitization of cancer cells by siRNA using targeted nanogel delivery.
Dickerson EB; Blackburn WH; Smith MH; Kapa LB; Lyon LA; McDonald JF
BMC Cancer; 2010 Jan; 10():10. PubMed ID: 20064265
[TBL] [Abstract][Full Text] [Related]
2. Strategy to enhance lung cancer treatment by five essential elements: inhalation delivery, nanotechnology, tumor-receptor targeting, chemo- and gene therapy.
Garbuzenko OB; Kuzmov A; Taratula O; Pine SR; Minko T
Theranostics; 2019; 9(26):8362-8376. PubMed ID: 31754402
[TBL] [Abstract][Full Text] [Related]
3. Tumor-specific delivery of therapeutic siRNAs by anti-EGFR immunonanoparticles.
Kim JS; Kim MW; Kang SJ; Jeong HY; Park SI; Lee YK; Kim HS; Kim KS; Park YS
Int J Nanomedicine; 2018; 13():4817-4830. PubMed ID: 30214190
[TBL] [Abstract][Full Text] [Related]
4. Peptide-functionalized nanogels for targeted siRNA delivery.
Blackburn WH; Dickerson EB; Smith MH; McDonald JF; Lyon LA
Bioconjug Chem; 2009 May; 20(5):960-8. PubMed ID: 19341276
[TBL] [Abstract][Full Text] [Related]
5. Combination Approach of YSA Peptide Anchored Docetaxel Stealth Liposomes with Oral Antifibrotic Agent for the Treatment of Lung Cancer.
Patel K; Doddapaneni R; Sekar V; Chowdhury N; Singh M
Mol Pharm; 2016 Jun; 13(6):2049-58. PubMed ID: 27070720
[TBL] [Abstract][Full Text] [Related]
6. Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma.
Varshosaz J; Farzan M
World J Gastroenterol; 2015 Nov; 21(42):12022-41. PubMed ID: 26576089
[TBL] [Abstract][Full Text] [Related]
7. Anti-EGF Receptor Aptamer-Guided Co-Delivery of Anti-Cancer siRNAs and Quantum Dots for Theranostics of Triple-Negative Breast Cancer.
Kim MW; Jeong HY; Kang SJ; Jeong IH; Choi MJ; You YM; Im CS; Song IH; Lee TS; Lee JS; Lee A; Park YS
Theranostics; 2019; 9(3):837-852. PubMed ID: 30809312
[TBL] [Abstract][Full Text] [Related]
8. A tumor-targeting cRGD-EGFR siRNA conjugate and its anti-tumor effect on glioblastoma in vitro and in vivo.
He S; Cen B; Liao L; Wang Z; Qin Y; Wu Z; Liao W; Zhang Z; Ji A
Drug Deliv; 2017 Nov; 24(1):471-481. PubMed ID: 28181832
[TBL] [Abstract][Full Text] [Related]
9. Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery.
Shen H; Rodriguez-Aguayo C; Xu R; Gonzalez-Villasana V; Mai J; Huang Y; Zhang G; Guo X; Bai L; Qin G; Deng X; Li Q; Erm DR; Aslan B; Liu X; Sakamoto J; Chavez-Reyes A; Han HD; Sood AK; Ferrari M; Lopez-Berestein G
Clin Cancer Res; 2013 Apr; 19(7):1806-15. PubMed ID: 23386691
[TBL] [Abstract][Full Text] [Related]
10. Dual peptide-mediated targeted delivery of bioactive siRNAs to oral cancer cells in vivo.
Alexander-Bryant AA; Zhang H; Attaway CC; Pugh W; Eggart L; Sansevere RM; Andino LM; Dinh L; Cantini LP; Jakymiw A
Oral Oncol; 2017 Sep; 72():123-131. PubMed ID: 28797448
[TBL] [Abstract][Full Text] [Related]
11. Actively targeted cetuximab conjugated gamma-poly(glutamic acid)-docetaxel nanomedicines for epidermal growth factor receptor over expressing colon cancer cells.
Maya S; Sarmento B; Lakshmanan VK; Menon D; Jayakumar R
J Biomed Nanotechnol; 2014 Aug; 10(8):1416-28. PubMed ID: 25016642
[TBL] [Abstract][Full Text] [Related]
12. Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.
Servidei T; Riccardi A; Mozzetti S; Ferlini C; Riccardi R
Int J Cancer; 2008 Dec; 123(12):2939-49. PubMed ID: 18803287
[TBL] [Abstract][Full Text] [Related]
13. Polypeptide cationic micelles mediated co-delivery of docetaxel and siRNA for synergistic tumor therapy.
Zheng C; Zheng M; Gong P; Deng J; Yi H; Zhang P; Zhang Y; Liu P; Ma Y; Cai L
Biomaterials; 2013 Apr; 34(13):3431-8. PubMed ID: 23375952
[TBL] [Abstract][Full Text] [Related]
14. Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer.
Yang X; Iyer AK; Singh A; Milane L; Choy E; Hornicek FJ; Amiji MM; Duan Z
Pharm Res; 2015 Jun; 32(6):2097-109. PubMed ID: 25515492
[TBL] [Abstract][Full Text] [Related]
15. Multifunctional nanogels for siRNA delivery.
Smith MH; Lyon LA
Acc Chem Res; 2012 Jul; 45(7):985-93. PubMed ID: 22181582
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor targeted methotrexate and small interfering RNA co-delivery.
Steinborn B; Truebenbach I; Morys S; Lächelt U; Wagner E; Zhang W
J Gene Med; 2018 Jul; 20(7-8):e3041. PubMed ID: 29949222
[TBL] [Abstract][Full Text] [Related]
17. Targeted in vivo delivery of EGFR siRNA inhibits ovarian cancer growth and enhances drug sensitivity.
Satpathy M; Mezencev R; Wang L; McDonald JF
Sci Rep; 2016 Nov; 6():36518. PubMed ID: 27819259
[TBL] [Abstract][Full Text] [Related]
18. EGFR aptamer-conjugated liposome-polycation-DNA complex for targeted delivery of SATB1 small interfering RNA to choriocarcinoma cells.
Dong J; Cao Y; Shen H; Ma Q; Mao S; Li S; Sun J
Biomed Pharmacother; 2018 Nov; 107():849-859. PubMed ID: 30142547
[TBL] [Abstract][Full Text] [Related]
19. Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth.
Merritt WM; Lin YG; Spannuth WA; Fletcher MS; Kamat AA; Han LY; Landen CN; Jennings N; De Geest K; Langley RR; Villares G; Sanguino A; Lutgendorf SK; Lopez-Berestein G; Bar-Eli MM; Sood AK
J Natl Cancer Inst; 2008 Mar; 100(5):359-72. PubMed ID: 18314475
[TBL] [Abstract][Full Text] [Related]
20. Targeted delivery of platinum-taxane combination therapy in ovarian cancer.
Desale SS; Soni KS; Romanova S; Cohen SM; Bronich TK
J Control Release; 2015 Dec; 220(Pt B):651-9. PubMed ID: 26381902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
